-
公开(公告)号：US20090081240A1
公开(公告)日：2009-03-26
申请号：US12244170
申请日：2008-10-02
申请人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Spee , Michael Wilken
发明人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkaer , Kristian Kjaergaard , Pieter Spee , Michael Wilken
CPC分类号： C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许哺乳动物受试者中NK细胞细胞毒性增强的抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20120208237A1
公开(公告)日：2012-08-16
申请号：US13347832
申请日：2012-01-11
申请人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagné , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thórólfsson , Søren Berg Padkær , Kristian Kjaergaard , Pieter Spee , Michael Wilken
发明人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagné , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thórólfsson , Søren Berg Padkær , Kristian Kjaergaard , Pieter Spee , Michael Wilken
CPC分类号： C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US08119775B2
公开(公告)日：2012-02-21
申请号：US12244170
申请日：2008-10-02
申请人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagné , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thórólfsson , Søren Berg Padkær , Kristian Kjaergaard , Pieter Spee , Michael Wilken
发明人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurent Gauthier , Francois Romagné , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thórólfsson , Søren Berg Padkær , Kristian Kjaergaard , Pieter Spee , Michael Wilken
CPC分类号： C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US08614307B2
公开(公告)日：2013-12-24
申请号：US13347832
申请日：2012-01-11
申请人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurant Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkjaer , Kristian Kjaergaard , Petrus Johannes Loius Spee , Milchael Wilken
发明人： Alessandro Moretta , Mariella Della Chiesa , Pascale Andre , Laurant Gauthier , Francois Romagne , Peter Andreas Nicolai Reumert Wagtmann , Ivan Svendsen , Stefan Zahn , Anders Svensson , Matthias Thorolfsson , Soren Berg Padkjaer , Kristian Kjaergaard , Petrus Johannes Loius Spee , Milchael Wilken
IPC分类号： C07H21/04
CPC分类号： C07K16/42 , C07K16/28 , C07K16/2803 , C07K2299/00 , C07K2317/21 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92
摘要： Compositions and methods for regulating an immune response in a subject are described. More particularly, described are human antibodies that regulate the activity of NK cells and allow a potentiation of NK cell cytotoxicity in mammalian subjects, and antibodies having antigen-binding properties similar to those of human monoclonal antibody 1-7F9 or 1-4F1. Described also are also fragments and derivatives of such antibodies, as well as pharmaceutical compositions comprising the same and their uses, particularly for use in therapy, to increase NK cell activity or cytotoxicity in subjects.
摘要翻译： 描述了用于调节受试者的免疫应答的组合物和方法。 更具体地，描述了调节NK细胞活性并允许在哺乳动物受试者中增强NK细胞细胞毒性的人抗体，以及具有与人单克隆抗体1-7F9或1-4F1类似的抗原结合特性的抗体。 还描述了这种抗体的片段和衍生物，以及包含其的药物组合物及其用途，特别是用于治疗，以增加受试者的NK细胞活性或细胞毒性。
-
公开(公告)号：US20090075340A1
公开(公告)日：2009-03-19
申请号：US12244101
申请日：2008-10-02
申请人： Soren Berg Padkaer , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard , Anders Svensson
发明人： Soren Berg Padkaer , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard , Anders Svensson
IPC分类号： C12P21/00 , C07K16/00 , A61K39/395 , C12N5/06 , C40B30/04 , A61K39/00 , C07H21/00 , C12N15/63 , C12N5/10
CPC分类号： C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
摘要翻译： 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来减少或阻断HLA结合。
-
公开(公告)号：US20080305117A1
公开(公告)日：2008-12-11
申请号：US11813402
申请日：2006-01-06
申请人： Soren Berg Padkaer , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard
发明人： Soren Berg Padkaer , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjaergaard
IPC分类号： A61K39/395 , C07K16/00 , C12N5/00 , G01N33/53 , C07H21/00 , C12N15/63 , C12P21/00 , A61P37/00
CPC分类号： C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, 5 upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as mono-clonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
摘要翻译： 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了用于减少KIR介导的NK细胞细胞毒性抑制的单克隆抗体的方法和试剂，而不通过例如还原或阻断KIR二聚化来降低或阻断HLA结合。
-
公开(公告)号：US08388970B2
公开(公告)日：2013-03-05
申请号：US12244101
申请日：2008-10-02
申请人： Søren Berg Padkær , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
发明人： Søren Berg Padkær , Peter Andreas Nicolai Reumert Wagtmann , Pieter Spee , Stefan Zahn , Kristian Kjærgaard , Anders Svensson
IPC分类号： A61K39/395 , A61K39/00
CPC分类号： C07K16/2803 , C07K16/28 , C07K2299/00 , C07K2317/55 , C07K2317/73 , C07K2317/76
摘要： The present invention relates to agents and methods that are capable of augmenting NK-mediated killing of target cells by reducing inhibitory KIR signalling without reducing the binding of KIR to HLA-C. As described herein, transduction of negative signaling via KIR, upon binding of KIR to its HLA class I ligand, can involve a ligand-binding induced, conformational reorientation of the KIR molecules allowing interactions to form between adjacent KIRs in specific domains, leading to accelerated clustering. Methods and agents such as monoclonal antibodies for reducing KIR-mediated inhibition of NK cell cytotoxicity without reducing or blocking HLA-binding by, e.g., reducing or blocking dimerization of KIR, are provided.
摘要翻译： 本发明涉及能够通过减少抑制性KIR信号而不降低KIR与HLA-C的结合来增强NK介导的靶细胞杀伤的试剂和方法。 如本文所述，在KIR与其HLA I类配体结合时通过KIR转导负向信号可涉及KIR分子的配体结合诱导的构象重新取向，允许在特定结构域中的相邻KIR之间形成相互作用，从而导致 加速聚类。 提供了诸如单克隆抗体的方法和试剂，用于减少KIR介导的NK细胞细胞毒性的抑制，而不通过例如还原或阻断KIR的二聚化来减少或阻断HLA结合。
-
公开(公告)号：US20130164299A1
公开(公告)日：2013-06-27
申请号：US13807505
申请日：2011-06-28
申请人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
发明人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
IPC分类号： C07K16/18
CPC分类号： C07K16/2851 , C07K16/18 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/6872
摘要： The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1- and CD161-expressing cells play a role in disease pathogenesis.
摘要翻译： 本发明涉及能够特异性结合凝集素样转录物1（LLT1）的单克隆抗体，编码这种抗体的多核苷酸和表达这种抗体的细胞。 本发明的抗体可用于治疗自身免疫疾病和癌症，其中表达LLT1和CD161的细胞在疾病发病中起作用。
-
公开(公告)号：US09127052B2
公开(公告)日：2015-09-08
申请号：US13807505
申请日：2011-06-28
申请人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
发明人： Petrus Johannes Louis Spee , Peter Andreas Nicolai Reumert Wagtmann , Stefan Zahn , Elisabeth D. Galsgaard , Birgitte Friedrichsen , Véronique Braud
CPC分类号： C07K16/2851 , C07K16/18 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92 , G01N33/6872
摘要： The present invention relates to monoclonal antibodies that are capable of specifically binding to lectin-like transcript 1 (LLT1), to polynucleotides encoding such antibodies and to cells that express such antibodies. Antibodies of the invention have utility in the treatment of autoimmune diseases and cancer, in which LLT1-and CD161-expressing cells play a role in disease pathogenesis.
摘要翻译： 本发明涉及能够特异性结合凝集素样转录物1（LLT1）的单克隆抗体，编码这种抗体的多核苷酸和表达这种抗体的细胞。 本发明的抗体可用于治疗自身免疫疾病和癌症，其中表达LLT1和CD161的细胞在疾病发病中起作用。
-
公开(公告)号：US20050106139A1
公开(公告)日：2005-05-19
申请号：US10699362
申请日：2003-10-31
申请人： Ivan Svendsen , Kristian Kjaergaard , Stefan Zahn
发明人： Ivan Svendsen , Kristian Kjaergaard , Stefan Zahn
IPC分类号： A61K39/395 , C07K16/36 , C07K16/44
CPC分类号： C07K16/36 , A61K2039/505 , C07K2317/24
摘要： Provided are novel isolated humanized antibodies that immunoreact with human tissue factor (TF) so as to inhibit the binding of coagulation factor Vila (FVIIa), pharmaceutical compositions comprising the same, methods of making the same, cells producing such antibodies, and methods of treating disease comprising administering such antibodies and/or compositions to a subject in need thereof. General methods for preparing humanized antibodies also are provided.
摘要翻译： 提供了与人组织因子（TF）免疫反应的新型分离的人源化抗体，以抑制凝血因子Vila（FVIIa）的结合，包含其的药物组合物，其制备方法，产生此类抗体的细胞，以及治疗方法 疾病，包括向有需要的受试者施用此类抗体和/或组合物。 还提供了制备人源化抗体的一般方法。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.054 秒)